These findings provide a strong biological rationale for extending the use of NECTIN4-targeted therapies such as EV to patients with brain MET.<h4>Patient summary</h4>We found that tumor samples from patients with cancer of the urinary tract that had spread to the brain had higher expression of a gene called NECTIN4 (67%). The gene discussed is NECTIN4; the disease is neoplasm.